@article { author = {}, title = {Compound HRAS/PIK3CA Mutations in Chinese Patients with Alveolar Rhabdomyosarcomas}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {15}, number = {4}, pages = {1771-1774}, year = {2014}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {The rhabdomyosarcoma (RMS) is the most common type of soft tissue tumor in children and adolescents;yet only a few screens for oncogenic mutations have been conducted for RMS. To identify novel mutations andpotential therapeutic targets, we conducted a high-throughput Sequenom mass spectrometry-based analysis of238 known mutations in 19 oncogenes in 17 primary formalin-fixed paraffin-embedded RMS tissue samples andtwo RMS cell lines. Mutations were detected in 31.6% (6 of 19) of the RMS specimens. Specifically, mutations inthe NRAS gene were found in 27.3% (3 of 11) of embryonal RMS cases, while mutations in NRAS, HRAS, andPIK3CA genes were identified in 37.5% (3 of 8) of alveolar RMS (ARMS) cases; moreover, PIK3CA mutationswere found in 25% (2 of 8) of ARMS specimens. The results demonstrate that tumor profiling in archival tissuesamples is a useful tool for identifying diagnostic markers and potential therapeutic targets and suggests thatthese HRAS/ PIK3CA mutations play a critical role in the genesis of RMS.}, keywords = {Rhabdomyosarcoma,massARRAY system,Mutation,oncogene,HRAS/PIK3CA}, url = {https://journal.waocp.org/article_28828.html}, eprint = {https://journal.waocp.org/article_28828_4873bccc3dcbc82212d254a07f4808ea.pdf} }